

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM750375

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest at Reel/Frame 6160/0787		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
NXT Capital, LLC		08/22/2022	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Wellspring Pharmaceutical Corporation		
Street Address:	5911 N. Honore Avenue, Suite 211		
City:	Sarasota		
State/Country:	FLORIDA		
Postal Code:	34243		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 20			
Property Type	Number	Word Mark	
Registration Number:	4598157	FDS PERSONALS	
Registration Number:	4580860	FDS	
Registration Number:	4199375	KEEP STOMACHS CALM AND CARRY ON	
Registration Number:	3835714	FEMININE.DISCREET.SENSUAL.	
Registration Number:	3877422	BARRIERE	
Registration Number:	3674239	GLAXAL BASE	
Registration Number:	3664440	GLAXAL BASE	
Registration Number:	2599688		
Registration Number:	2606065		
Registration Number:	2504774	BACTINE	
Registration Number:	2264700		
Registration Number:	0997843	MICATIN	
Registration Number:	0863268	FDS	
Registration Number:	0831204	FDS	
Registration Number:	0800495	BACTINE	
Registration Number:	0800199	BACTINE	
Registration Number:	0697007	BONINE	
Registration Number:	0536728	EMETROL	
Registration Number:	0525085	BACTINE	

CH \$515.00 4598157

Property Type	Number	Word Mark
Registration Number:	0378528	GELUSIL
CORRESPONDENCE DATA		
Fax Number:	6172359493	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6179517170	
Email:	ustrademarkmail@ropesgray.com	
Correspondent Name:	Catherine Murray	
Address Line 1:	Prudential Tower, 800 Boylston Street	
Address Line 2:	ROPES & GRAY LLP	
Address Line 4:	Boston, MASSACHUSETTS 02199-3600	
ATTORNEY DOCKET NUMBER:	AGW-291-005	
NAME OF SUBMITTER:	Catherine Murray	
SIGNATURE:	/cmurray/	
DATE SIGNED:	08/22/2022	
Total Attachments: 5		
source=Wellspring - IP Release (8.22.22) [Executed](134512909.1)#page1.tif		
source=Wellspring - IP Release (8.22.22) [Executed](134512909.1)#page2.tif		
source=Wellspring - IP Release (8.22.22) [Executed](134512909.1)#page3.tif		
source=Wellspring - IP Release (8.22.22) [Executed](134512909.1)#page4.tif		
source=Wellspring - IP Release (8.22.22) [Executed](134512909.1)#page5.tif		

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY COLLATERAL**

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL (this "Release"), dated as of August 22, 2022, is made by NXT Capital, LLC, as administrative agent (the "Agent") in favor of Wellspring Pharmaceutical Corporation, a Delaware corporation (the "Grantor"), as follows:

WITNESSETH:

WHEREAS, pursuant to that certain Guarantee and Collateral Agreement dated as of September 25, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Guarantee and Collateral Agreement"), among the Grantor and the other parties party thereto in favor of the Agent, and those certain agreements described on Annex I attached hereto (each, an "IP Security Agreement" and collectively, the "IP Security Agreements"), the Grantor granted a security interest in certain collateral in favor of the Agent, including the IP Collateral (as hereinafter defined); and

WHEREAS, the Agent now desires to terminate and release the IP Security Agreements and the entirety of its security interest in the IP Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms set forth in this Release, the Agent hereby agrees as follows:

1. Definitions. The term "IP Collateral", as used herein, shall mean all of Grantor's right, title or interest in, or to any and all of the Trademarks and Patents, including the Trademarks and Patents listed on Annex II attached hereto. Capitalized terms not defined herein have the meanings set forth in the Guarantee and Collateral Agreement or the applicable IP Security Agreement, as applicable.

2. Release of Security Interest. The Agent, without recourse, representation or warranty and at the Grantor's sole cost and expense, hereby terminates and cancels the IP Security Agreements and terminates, cancels, releases, relinquishes and discharges, in its entirety, for the benefit of the Grantor, and its successors and assigns, its security interest in and to the IP Collateral and any and all right, title and interest of the Agent in, to and under the IP Collateral shall hereby be terminated, cancelled, released, relinquished and discharged. The Agent hereby authorizes the Grantor and its successors, assigns or other legal representatives to file this Release with the United States Patent and Trademark Office, at the sole expense of the Grantor, to evidence and effectuate the release and termination of the Agent's security interest in the IP Collateral.

3. Delivery by Facsimile. Delivery of an executed signature page to this Release by facsimile or electronic (including .pdf file) transmission shall be as effective as delivery of a manually signed counterpart of this Release. The parties hereby agree that the electronic signatures of the parties will have the same force and effect as a manual signatures.

4. Governing Law. THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[Signature page follows]

IN WITNESS WHEREOF, the undersigned has executed this Release by its duly authorized officer as of the date first above written.

NXT CAPITAL, LLC, as Agent

Julia Allman

By: julia.allman@nxtcapital.com

Name: Julia Allman

Title: Vice President

[Signature Page to Release of Security Interest in Intellectual Property Collateral]

ANNEX I


Trademark Security Agreement entered into by Wellspring Pharmaceutical Corporation in favor of the Agent, dated as of September 25, 2017 and recorded with the United States Patent and Trademark Office on September 25, 2017 at Reel/Frame 6160/0787.

Patent Security Agreement entered into by Wellspring Pharmaceutical Corporation in favor of the Agent, dated as of September 25, 2017 and recorded with the United States Patent and Trademark Office on September 25, 2017 at Reel/Frame 043685/0502.

ANNEX II

UNITED STATES TRADEMARK REGISTRATIONS

Trademark	Application Number/ Application Date	Registration Number/ Registration Date	Owner
FDS PERSONALS	85889897 3/28/2013	4598157 9/2/2014	WELLSPRING PHARMACEUTICAL CORPORATION
FDS	85761657 10/23/2012	4580860 8/5/2014	WELLSPRING PHARMACEUTICAL CORPORATION
KEEP STOMACHS CALM AND CARRY ON	85250507 2/24/2011	4199375 8/28/2012	WELLSPRING PHARMACEUTICAL CORPORATION
FEMININE.DISCREET.SENSUAL.	77578941 9/25/2008	3835714 8/17/2010	WELLSPRING PHARMACEUTICAL CORPORATION
BARRIERE	77572985 9/18/2008	3877422 11/16/2010	WELLSPRING PHARMACEUTICAL CORPORATION
GLAXAL BASE <i>Glaxal Base</i>	77545009 8/12/2008	3674239 8/25/2009	WELLSPRING PHARMACEUTICAL CORPORATION
GLAXAL BASE	77382002 1/28/2008	3664440 8/4/2009	WELLSPRING PHARMACEUTICAL CORPORATION
Design Only 	78075343 7/24/2001	2599688 7/23/2002	WELLSPRING PHARMACEUTICAL CORPORATION
Design Only 	78075345 7/24/2001	2606065 8/6/2002	WELLSPRING PHARMACEUTICAL CORPORATION
BACTINE	78036938 11/29/2000	2504774 11/6/2001	WELLSPRING PHARMACEUTICAL CORPORATION

Trademark	Application Number/ Application Date	Registration Number/ Registration Date	Owner
Design Only 	75480950 5/7/1998	2264700 7/27/1999	WELLSPRING PHARMACEUTICAL CORPORATION
MICATIN	73000354 9/7/1973	0997843 11/12/1974	WELLSPRING PHARMACEUTICAL CORPORATION
FDS	72300507 6/17/1968	0863268 1/7/1969	WELLSPRING PHARMACEUTICAL CORPORATION
FDS	72256792 10/20/1966	0831204 6/27/1967	WELLSPRING PHARMACEUTICAL CORPORATION
BACTINE	72201720 9/11/1964	0800495 12/14/1965	WELLSPRING PHARMACEUTICAL CORPORATION
BACTINE	72201719 9/11/1964	0800199 12/14/1965	WELLSPRING PHARMACEUTICAL CORPORATION
BONINE	72081199 9/11/1959	0697007 5/3/1960	INSIGHT PHARMACEUTICALS LLC
EMETROL	71589160 12/10/1949	0536728 1/16/1951	WELLSPRING PHARMACEUTICAL CORPORATION
BACTINE	71570426 12/13/1948	0525085 5/9/1950	WELLSPRING PHARMACEUTICAL CORPORATION
GELUSIL	71427151 1/4/1940	0378528 6/11/1940	WELLSPRING PHARMACEUTICAL CORPORATION

UNITED STATES PATENT REGISTRATIONS

COUNTRY	TITLE	APPLICATION NO.	PATENT NO.	OWNER
United States	SUSTAINED- RELEASED FRAGRANCE DELIVERY SYSTEM	11/076,348	7,638,477	Wellspring Pharmaceutical Corporation